Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 21, 2026.

To Protect and to Preserve: Novel Preservation Strategies for Extracellular Vesicles

Gina D. Kusuma, Mehri Barabadi, Jean L. Tan and 3 more

Frontiers in Pharmacology · 2018 · Review

doi:10.3389/fphar.2018.01199

Abstract

Extracellular vesicles (EVs)-based therapeutics are based on the premise that EVs shed by stem cells exert similar therapeutic effects and these have been proposed as an alternative to cell therapies. EV-mediated delivery is an effective and efficient system of cell-to-cell communication which can confer therapeutic benefits to their target cells. EVs have been shown to promote tissue repair and regeneration in various animal models such as, wound healing, cardiac ischemia, diabetes, lung fibrosis, kidney injury, and many others. Given the unique attributes of EVs, considerable thought must be given to the preservation, formulation and cold chain strategies in order to effectively translate exciting preclinical observations to clinical and commercial success. This review summarizes current understanding around EV preservation, challenges in maintaining EV quality, and also bioengineering advances aimed at enhancing the long-term stability of EVs.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 21, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Interest in extracellular vesicles (EVs) has escalated over the last decade. This has been particularly the case in clinical applications, including the application of EV biology to biomarker discovery, vaccine development, drug delivery, and EV-based therapeutics. EVs are key players in intercellular communication and they are protected from degradation by their lipid bilayer membrane that envelop bioactive cargo. These include proteins, sugars, lipids, and nucleic acids. EVs can be classified based on their size, i.e., apoptotic bodies (>1000 nm), microvesicles (100 – 1000 nm), and exosomes (30 – 150 nm). The field of EV research is rapidly gaining momentum and overlaps with the newer field of bioengineering where synthetic liposomes, biomimetic vesicles, and nanoparticles have been utilized to package bioactive cargo. In this review, we assess current strategies employed for EV preservation and bioengineering advances aimed at enhancing long term stability of EVs intended for clinical use.

Composition and Cargo of EVs

Extracellular vesicles are ideal intercellular transporters of biomolecules. They express surface molecules that enable tissue- or cell-specific targeting. Upon reaching their recipient cells, EVs can induce signaling via receptor-ligand interaction, or be internalized by endocytosis to deliver their cargo. The term “exosomes” is generally used to describe most EVs globally. In an attempt to standardize nomenclature and improve accuracy of data interpretation, the International Society of Extracellular Vesicles (ISEV) published a set of guidelines in 2014 that outlined the so-called minimal requirements to define EVs. The collective term of EVs will be used throughout this review since the definition of exosomes remains contentious. Given the increasing interest in EVs and their potential use in regenerative medicine, isolated EVs must be carefully characterized – this necessarily requires a complex combination of protein profiling (proteomics, western blotting, or flow cytometry), imaging, and nanoparticle tracking analysis.

Extracellular vesicles are secreted by virtually all cell types and present in all bodily fluids. An online public database, ExoCarta1 has been created to curate this diverse body of data, with the goal of facilitating and encouraging collaborative research. This public repository is being continuously updated with new contributions from various EV researchers.

Extracellular vesicles are enriched in membrane proteins and cellular proteins, including the tetraspanins CD63, CD9, CD81, Alix, Tsg101, MHC1 and heat shock proteins. The protein cargo of EVs include cell-specific proteins which are responsible for specific fates and functions, such as: cell adhesion (integrins, ICAM), signal transductions (G proteins, β-catenin, protein kinases), and intracellular trafficking (RAB, GTPases, annexins). The lipid contents of EVs include ceramides, sphingomyelins, phosphatidylserine, and cholesterol. This unique lipid composition is thought to facilitate the uptake of EVs by recipient cells. The lipid composition of EV membranes also play significant roles in intercellular signaling and provide structural stability. Furthermore, the surfaces of EVs are surrounded by polysaccharides and glycan. The nucleic acid cargo in EVs such as mitochondrial DNA, genomic DNA, mRNA, miRNA, and long non-coding RNA have already been documented extensively. Importantly, exosomal RNA play functional roles in EV-mediated cellular communication where exosomal mRNA can be translated into proteins in recipient cells and exosomal microRNA (miR) may regulate gene expression in recipient cells.

EVs Molecular Cargo Involved in Therapeutic Benefits/Immunomodulation

EV-mediated delivery is an effective and efficient system to confer therapeutic benefits to their target destinations. The contents of EV cargo can be heavily influenced by their producer cells and different cell types will secrete a range of functional effects on recipient cells. The ability of EVs to interact with recipient cells is likely to be affected by the presence of adhesion molecules (e.g., integrins) on the surface of EVs, and this will contribute to the cell or tissue specificity of EVs.

Extracellular vesicles exhibit intrinsic therapeutic benefits, for example, EVs can be used as gene delivery vehicles without inducing adverse immune reactions. This contrasts with the more commonly used gene therapy vehicles such as viral vectors and lipid nanoparticles which are immunogenic.

There are a number of different strategies to identify and validate EV-mediated cargo delivery into recipient cells. For example, labeling EVs with a tracking dye can result in a quantifiable increase in fluorescence in the recipient cells once exosome uptake occurs. Alternatively, EV-associated RNA labeled with a radioactive tracer can be used to demonstrate uptake by recipient cells. For the purposes of this review, we have summarized recent studies describing the therapeutic use of EVs from human cell types in Table 1.

EV-based therapeutics have been proposed as an alternative to cellular therapy, where the latter refers to the use of intact, living cells. In particular, cell therapy exploits the ability of the cellular products to secrete a complex repertoire of bioactive factors including EVs. However, the widespread use of cell therapies has been limited by challenges in the scalability and reproducibility of cell manufacturing. A paradigm shift toward cell-free therapies has now captured the attention of this sector, where the potential of EVs is being explored. In comparison to cells, EVs have a simplified cold chain process, and have a lower risk profile due to the unlikelihood of spontaneous DNA transformation or immune rejection. Furthermore, EVs can be used directly, either alone or in combination with other pharmacological agents.

Preclinical Evaluation of EV-Based Therapeutics

Stem cell-derived EVs have been shown to modulate the immune response from both the innate and adaptive immunity., showed that BMMSCs-EVs induced regulatory dendritic cell (DC) phenotypes with the ability to inhibit T cell activity, while ESC-EVs can reportedly promote M2 macrophage polarization, upregulate Treg numbers and downregulate splenocyte proliferation. Additionally, MSC-EVs were reported to promote Treg proliferation and inhibit autoreactive T cell activity, as well as induce polymyxin-resistant MyD88-dependent secreted embryonic alkaline phosphatase expression in THP-1 cells. In a mouse model of myasthenia gravis, MSC-EVs reduced T cell-dependent immunoactivation, ameliorated autoimmune injury, and prolonged survival time. Additionally, showed that MSC-EVs modulate immune responses in two different autoimmune mouse models. In a mouse model of type I diabetes, they showed that MSC-EVs delayed the onset of type I diabetes through modulation of IL-1β mediated pancreatic B-cell destruction. Similarly, they showed that 30 μg of MSC-EVs attenuated uveoretinitis triggered by Th1/Th17 activation.

In murine models of kidney injury, MSC-derived EVs protected against renal injury by reducing levels of creatinine, uric acid, lymphocyte response and fibrosis through shuttling miR-let7c to induce renal tubular cell proliferation. In a murine model of carbon tetrachloride-induced hepatic injury, concurrent treatments of MSC-EVs attenuated the injury by increasing the proliferation, survival and prevented the apoptosis of hepatocytes. In animal models of lung injury, MSC and hAEC-EVs have been shown to reduce pulmonary inflammation, improved lung tissue recovery and supported the proliferation of alveolar type II and bronchioalveolar stem cells. In models of stroke, MSC-EVs delivery of miR-133b directly to neurite cells reportedly enhanced the outgrowth of neurites resulting in increased proliferation of neuroblasts and endothelial cells. Additionally, Anderson et al. showed through a comprehensive proteomic analysis that MSC-derived EVs mediated angiogenesis via NF-κB signaling, while showed that UC MSC-EVs mediated angiogenesis via the Wnt4/β-catenin pathway.

The possibility for EV-based therapeutics to be developed from immune cells is also currently being explored. EVs from dendritic cells have been engineered in various ways to help combat autoimmune diseases. These include stimulating DCs with IFNγ to express miRNAs which stimulate myelination, and reduce oxidative stress. Immature DCs (iDCs)-EVs, which have not conformed to their mature role in expressing MHC and co-stimulatory molecules, displayed immunosuppressive properties in autoimmune diseases. For instance, in a mouse model of autoimmune neuromuscular disorder; myasthenia gravis (MG) iDC-derived EVs prevented MG disorder by suppressing lymphocyte reactivity in vivo. Immune cell-derived EVs are relatively easy to isolate and as such can be beneficial as potential targets for autoimmune and cancer treatments.

Clinical Application of EV-Based Therapeutics

There is currently only a handful of clinical trials based on therapeutic EVs registered; all of which are currently still recruiting. However only one official trial has been reported to date using ascites-derived exosomes for the treatment of colorectal cancer. Additionally, in a letter to the editor, the use of stem cell-derived EV administered under compassionate care to patients suffering from graft vs. host disease (GvHD) recorded no adverse effects. The first study was dated back to 2008, while the second was published in 2014. Since then, there is a modest increase in the number of clinical trials with five out of seven using biologically derived EVs while the remaining are plant based EVs. These trials are currently recruiting and are expected to commence in the near future.

Current methods for EV manufacturing are inadequate. Indeed, scalable manufacturing of clinical grade EVs to meet market demands will be a major challenge for this emerging sector for the foreseeable future (Figure 1). Given the unique attributes of EVs, considerable thought must be given to the preservation, formulation, and cold chain strategies in order to effectively translate exciting preclinical observations to clinical and commercial success.

Conventional Methods for EVs Preservation

Since the commercial and clinical applications of EVs require standard criteria for long-term storage, cryopreservation methods have become a subject of growing interest. This section will describe the current understanding around EV preservation, challenges in maintaining EV stability, and their impact on long term storage and cold chain processes. Table 2 highlights the current preservation methods used in EV for therapeutics purposes.

Cryopreservation

Cryopreservation with cryoprotectants (CPAs) is a widely accepted procedure to maintain protein stability and prevent osmotic damage. Optimum EV dehydration can be achieved in the presence of CPAs by increasing viscosity, impacting the kinetics of ice nucleation, and allowing regulated extracellular ice growth during controlled cooling. However, excessively low concentrations of CPAs may result in chilling shock, which is defined as the damage caused by the freezing process. On the other hand, excessively high concentrations of CPAs can be toxic. Thus, a balance is needed to achieve optimal cryopreservation.

CPAs refer to a diverse range of sugars, diols, and amino acids which work to stabilize biomolecules in a variety of ways depending on their molecular mass, examples of CPA application in molecular and cell biology is described on Table 3. Penetrating CPAs (pCPA) have low molecular weights (<100 Da) and work by permeating across the lipid bilayer membranes to stabilize the biomolecules (Figure 2). In contrast, non-penetrating CPAs (npCPA) remain external to the vesicle due to their high molecular mass (180–594 Da) and prevent cryodamage from hyperosmotic lysis. Notably, there is a growing body of evidence suggesting a combination of both pCPAs and npCPAs is more effective (Table 3).

A wide range of substances have been used as stabilizers in conventional cryopreservation methods. Specifically, disaccharides are a safe choice for EV-based therapeutics. Trehalose, a natural non-reducing disaccharide, is an FDA-approved CPA for a wide range of proteins and cell products. Following reports showing the importance of adding pCPAs and npCPAs, trehalose was suggested as an ideal candidate to preserve hematopoietic and embryonic stem cells as well as other progenitor cells for therapeutic applications. Trehalose prevented aggregation by avoiding internal ice formation in biological particles such as liposomes and EVs. The addition of trehalose also increased the colloidal stability of EVs.

Lyophilisation/Freeze Drying

Freeze-drying or lyophilisation is currently thought to be the most reliable method to preserve thermolabile materials such as proteins, peptides, vaccines, colloidal carriers, EVs and viruses. The first step in lyophilisation involves the freezing or solidification of the EVs, when cooling rate correlates inversely with the size of the ice crystal. The crystallized material is then sublimated directly into water vapor. Freezing and dehydration stresses generated during lyophilisation may result in destructive effects on the structure of biomolecules within the EV, and thus necessitates the use of CPAs in the formulation to protect the EVs and their cargo.

The stability of lyophilised EVs significantly extends their shelf life, lowers storage demands, and costs owing to a simplified cold chain. For example, the best storage temperature reported for lyophilised EVs isolated from cardiospheres was 4°C. The most common stabilizers used in lyophilisation are disaccharides such as glucose, lactose, sucrose and trehalose, which work by replacing the hydration sphere around the EVs through a hydrogen bonding interaction with phospholipid head groups to form an amorphous sugar glass. The glassy state produced in the presence of disaccharides prevent fusion of products or protein destabilization.

Trehalose has been suggested as the most effective disaccharide to preserve EVs during lyophilisation. This promising technique is an FDA-approved method for a range of proteins, liposomes and nanoparticles that enables their use in the pharmaceutical industry.

Spray Drying

Spray drying is a common method for producing a wide variety of therapeutic agents including vaccines, peptides and proteins for inhaled delivery. This single-step process substantially reduces the need for expensive equipment and lengthier multi-step processes. Spray drying is scalable and operators are able to tune the particle size of the final product by controlling the spray droplet size and solute concentration, thereby providing a major point of difference from lyophilisation where the particle size reduction can occur only through mechanical milling.

Spray drying involves an initial step of atomising the solution containing EVs. These droplets are rapidly converted into a dry powder using heated gas. Spray drying is a continuous process and can be both automated and instrumented for enhanced process control. The reduction in moisture content of particles formed during the spray drying process generally increases the stability of the biopharmaceuticals in these particles: the residual moisture acts as a plasticiser to reduce glass transition temperature of the particle solid state, and its presence may also enhance chemical instability. Critical process parameters such as the rate at which EV solution is being fed into the system, the atomisation pressure and outlet temperature, can all affect the stability of the EVs and their cargo. These critical process parameters must therefore be identified and maintained within a narrow window. patented a technique to encapsulate the platelet rich solution EVs as a candidate for wound healing (US20160324794A1). However, further investigation is needed to apply this technique more broadly to the manufacturing and storage of EV-based therapeutics.

Challenges Associated With EVs Preservation

In order for EV-based therapeutics to be manufactured and used reproducibly, storage conditions must have minimal impact on EV structural integrity. The following section will discuss parameters known to affect EV composition, biological potency and structural integrity.

Storage Temperature and Shelf Life

There have been a number of studies conducted to determine the most favorable storage conditions for EVs. Focusing on EVs with intended therapeutic applications, EVs from human embryonic kidney (HEK) 293T cells, endothelial colony forming cells (ECFCs) and MSCs report -20°C as the highest temperature in which EVs are stable. These results are in line with the standard preservation temperature reported by ISEV for EVs storage. In contrast, another study has reported that -70°C is the best long-term storage temperature for EVs isolated using the Exo-Quick kit (System Biosciences, Palo Alto, CA, United States).

Freeze Thaw Stress

While freeze-thaw cycles do not affect the stability of EVs isolated from plasma and exosomal miRNA and different cell types like HEK293T, ECFCs and MSCs, other studies show that EVs can be structurally susceptible due to the exposure of vulnerable phosphatidylserine to repeated freeze-thaw cycles. This is an area that must be deconvoluted as EV-based therapeutics are being developed, in order to establish a clear product stability profile as required by regulatory bodies.

Overcoming Aggregation in EV Preparations

A preparation of EVs can be considered as a colloid – a solution in which microscopically dispersed particles are suspended. From this perspective, there are several known phenomena that can be applied to EVs, providing a rationale underlying the basis of possible approaches that can be used to increase the stability and quality of stored EVs. One of the major challenges in EV storage, particle aggregation, occurs when inter-particle attraction is greater than repulsion. Such interactions are governed by factors such as surface charge, hydrophobicity and fluidity. Strategies to prevent EV aggregation must therefore modify these factors to increase inter-particle repulsion and stabilize the colloidal solution.

Although EV biology is a relatively new field, EVs share many overarching structural features with liposomes – lipid bilayered vesicles that have been well-studied due to their utility as drug delivery vehicles. Looking toward liposome studies, the use of hydrophilic polymers as steric stabilizers may be a good strategy for preservation of a colloidal system. When using polymers, it is thought that the hydrophilic chains extend from the liposomes out into the solution thereby stabilizing the system so that the individual particles remain well-dispersed (Figure 3).

The most common polymer used in liposome stabilization is PEG (polyethylene glycol). Advantages of PEG include the fact that it is non-fouling, well-tolerated by the body, can be obtained in a wide range of molecular weights and end-group chemistries and that it is FDA approved for a range of medical applications. There are many examples in which liposomes have been PEGylated, i.e., the PEG chains are incorporated within the lipid bilayer during synthesis (e.g., PEGlyated liposomes to incorporate itraconazole, antifungal agent, as well as dopamine-loaded PEGylated immunoliposomes;; ). Although effective, such a strategy is unsuitable for EV stabilization. Coating the particles in polymer can have a similar effect and would be a much more suitable strategy for EV preservation, allowing EVs to be stabilized by the simple addition of polymer to the isolated preparation. Other polymers that have been used include the synthetic polymer PVA (polyvinylalcohol), and the naturally derived polysaccharides OPP (O-palmitoylpullulan), chitosan, and hyaluronic acid. Specific stabilization of EVs has thus far been limited to the use of trehalose. Addition of trehalose to solutions of EVs was proven to enhance colloidal stability during electroporation, for the modification of EV cargo. Addition of 25 mM trehalose to EVs derived from pancreatic beta cells was observed to narrow the particle size distribution (i.e., increase the stability) and improve the particle yield, presumably by also reducing loss of EVs through interactions with the walls of the storage vessel.

Biomaterial Scaffolds for EV Stability and Delivery

The matrix of tissues in the body hosts a population of vesicles, often termed matrix bound vesicles (MBVs). In a similar manner to the protection of growth factors by sequestration and release from the extracellular matrix (ECM), the binding of these vesicles has a vital role in enhancing their stability and biological availability. Although, there is still debate as to whether MBVs possess all of the characteristics required to be defined as an EV, there is also evidence that EVs can bind to ECM components; for example, a study by Narayanan et al. showed binding of MSC-derived EVs to bind to both fibronectin and collagen type I in the ECM. Such interactions between EVs and the ECM are likely mediated by adhesion receptors, known to be present on the exosomal membrane, including integrins, tetraspanins, and ICAM-1.

In the case of MBVs, interaction with the matrix has proven to enhance their stability. MBVs can survive chemical, enzymatic and detergent-based treatments and subsequently induce changes in cellular behavior. These intriguing findings indicate that incorporation of EVs with ECM or biomaterial components may be a powerful tool to both enhance EV stability and provide a controlled spatiotemporal release within the body. This premise is supported by a few early studies in which EVs have been incorporated into biomaterial constructs for delivery. For example, stabilized MSC-derived EVs by incorporation into porous tricalcium phosphate (β-TCP) scaffolds. In doing so they demonstrated that EVs could be released over several days and further that the function of these EVs in promoting bone repair was retained. In another study, Shi et al. combined MSC-EVs with a hydrogel synthesized from chitosan and silk, showing that EVs incorporated into the biomaterial could be released over time and retained their function to improve wound healing. Although, in its infancy, these studies uniting EV biology and bioengineering provide an exciting glimpse into future applications of biomaterials to preserve and deliver EVs for therapeutic application.

Future Directions

Given that EVs largely retain the properties of their cells of origin, it is unsurprising that cell therapy companies have jumped on this particular bandwagon in order to maximize the proprietary cell lines. For example, Capricor Therapeutics (Beverly Hills, CA, United States) are investigating the clinical potential of CAP-2003, which refer to the EVs produced by their proprietary cardiosphere-derived cells. Capricor has made efforts to evaluate the regenerative potential of these cardiosphere-derived EVs on diseases involving inflammation and fibrosis. Similarly, cell therapy company specializing in neurological disease, ReNeuron, has sought to do the same with EVs from their proprietary CTX neural cell line, which are currently in Phase IIb clinical trials for US-based patients living with post-stroke disabilities. It is likely that we will need an emergence of EV-based therapeutics from other cell therapy companies as the proverbial penny drops – there is immense value in what was essentially considered a waste product of cell manufacturing.

Regardless of whether EVs will be used for the purposes of regenerative medicine, cancer vaccination, veterinary or agriculture, there is an obvious need to develop methods to reliably store, transport and apply the EVs. Of these considerations, storage of the EVs is perhaps the most critical aspect of the supply chain. The stability of the EVs in their storage medium necessarily dictates the rigidity of the cold chain and will have direct impact on the cost of goods. Investment into technologies that refine the stability of EVs will likely afford significant cost savings downstream. The storage medium will also impact the final formulation of the EV therapeutic as challenges around solubility of injectables and particle size of aerosols must be considered. These factors will have knock-on effects on biodistribution and therapeutic efficacy. As such, rigorous preclinical testing should be designed with this in mind, in order to expedite product development and facilitate regulatory approval.

Conclusion

The FDA approval of chimeric antigen receptor T cells (CAR-T), Kymriah (Novartis) for refractory B-cell precursor acute lymphoblastic leukemia in August 2017, heralded the dawn of a new age for cell therapies. There are, however, broader implications for these approved cell therapies. Chief amongst these is the growing acceptance of cellular therapies and regenerative medicine in mainstream clinical care. However, the relative high cost of goods remains prohibitive for cellular therapies. Challenges in scalable manufacturing, maintenance of a master cell bank, complex cold chain logistics and ambiguity around product release criteria, have led to lengthy delays in realizing the potential of cellular therapies. While regulatory hurdles for this new class of biologics remain a challenge to be met, it is likely that the relative stability of EVs will see a significantly expedited path to regulatory approval. Furthermore, as critical questions around scalable manufacturing and long-term preservation are answered, EV-based therapeutics may offer a more affordable form of regenerative medicine, thereby increasing market penetration and patient access. In essence, the development of novel preservation protocols tailored for EVs are likely to fast forward the manufacturing process to establish EVs as commercially viable therapeutics.

Author Contributions

GK, MB, JT, DM, JF, and RL contributed to the writing and editing of this manuscript. GK and JT prepared the figures. GK and MB prepared the tables.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 221

  1. 1.

    Abdelwahed W. Degobert G. Fessi H. (2006a ). A pilot study of freeze drying of poly(epsilon-caprolactone) nanocapsules stabilized by poly(vinyl alcohol): formulation and process optimization. Int. J. Pharm. 309 178–188.

    Not in our library10.1016/j.ijpharm.2005.10.003

  2. 2.

    Abdelwahed W. Degobert G. Fessi H. (2006b ). Investigation of nanocapsules stabilization by amorphous excipients during freeze-drying and storage. Eur. J. Pharm. Biopharm. 63 87–94.

    Not in our library10.1016/j.ejpb.2006.01.015

  3. 3.

    Admyre C. Bohle B. Johansson S. M. Focke-Tejkl M. Valenta R. Scheynius A. (2007 ). B cell-derived exosomes can present allergen peptides and activate allergen-specific T cells to proliferate and produce TH2-like cytokines. J. Allergy Clin. Immunol. 120 1418–1424.

    Not in our library10.1016/j.jaci.2007.06.040

  4. 4.

    Alihosseini F. Ghaffari S. Dabirsiaghi A. R. Haghighat S. (2015 ). Freeze-drying of ampicillin solid lipid nanoparticles using mannitol as cryoprotectant. Braz. J. Pharm. Sci. 51 797–802.

    Not in our library10.1590/s1984-82502015000400005

  5. 5.

    Almalik A. Alradwan I. Kalam M. A. Alshamsan A. (2017 ). Effect of cryoprotection on particle size stability and preservation of chitosan nanoparticles with and without hyaluronate or alginate coating. Saudi Pharm. J. 25 861–867.

    Not in our library10.1016/j.jsps.2016.12.008

  6. 6.

    Amarnath S. Foley J. E. Farthing D. E. Gress R. E. Laurence A. Eckhaus M. A. (2015 ). Bone marrow-derived mesenchymal stromal cells harness purinergenic signaling to tolerize human th1 cells in vivo. Stem Cells 33 1200–1212.

    Not in our library10.1002/stem.1934

  7. 7.

    Anderson J. D. Johansson H. J. Graham C. S. Vesterlund M. Pham M. T. Bramlett C. S. (2016 ). Comprehensive proteomic analysis of mesenchymal stem cell exosomes reveals modulation of angiogenesis via nuclear factor-kappaB signaling. Stem Cells 34 601–613.

    Not in our library10.1002/stem.2298

  8. 8.

    Ann E. (2005 ). Available at: Intact cell fzw /.1

    Not in our library

  9. 9.

    Arslan F. Lai R. C. Smeets M. B. Akeroyd L. Choo A. Aguor E. N. E. (2013 ). Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury. Stem Cell Res. 10 301–312.

    Not in our library10.1016/j.scr.2013.01.002

  10. 10.

    Badowski M. Muise A. Harris D. T. (2014 ). Mixed effects of long-term frozen storage on cord tissue stem cells. Cytotherapy 16 1313–1321.

    Not in our library10.1016/j.jcyt.2014.05.020

  11. 11.

    Batista B. S. Eng W. S. Pilobello K. T. Hendricks-Munoz K. D. Mahal L. K. (2011 ). Identification of a conserved glycan signature for microvesicles. J. Proteome Res. 10 4624–4633.

    Not in our library10.1021/pr200434y

  12. 12.

    Beattie G. M. Crowe J. H. Lopez A. D. Cirulli V. Ricordi C. Hayek A. (1997 ). Trehalose: a cryoprotectant that enhances recovery and preserves function of human pancreatic islets after long-term storage. Diabetes Metab. Res. Rev. 46 519–523.

    Not in our library10.2337/diab.46.3.519

  13. 13.

    Behfar A. (2016 ). Exosome delivery technololgy. Patent No: US20160324794

    Not in our library

  14. 14.
    Cryoprotectant Toxicity: Facts, Issues, and Questions · 2015
    Corrected
  15. 15.

    Bissoyi A. Pramanik K. (2013 ) Effects of non-toxic cryoprotective agents on the viability of cord blood derived MNCs. Cryo. Letters 34 453–465.

    Not in our library

  16. 16.
    Trehalose prevents aggregation of exosomes and cryodamage · 2016
    No notice
  17. 17.

    Bozzo T. (1999 ). Blood component recalls. Transfusion 39 439–441.

    Not in our library10.1046/j.1537-2995.1999.39050439.x

  18. 18.

    Broadhead J. Edmond Rouan S. K. Rhodes C. T. (1992 ). The spray drying of pharmaceuticals. Drug Dev. Ind. Pharm. 18 1169–1206.

    Not in our library10.3109/03639049209046327

  19. 19.

    Bruder S. P. Jaiswal N. Haynesworth S. E. (1997 ). Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation. J. Cell. Biochem. 64 278–294.

    Not in our library10.1002/(sici)1097-4644(199702)64:2<278::aid-jcb11>3.0.co;2-f

  20. 20.
    Microvesicles Derived from Mesenchymal Stem Cells Enhance Survival in a Lethal Model of Acute Kidney Injury · 2012
    No notice
  21. 21.

    Bruno S. Grange C. Deregibus M. C. Calogero R. A. Saviozzi S. Collino F. (2009 ). Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J. Am. Soc. Nephrol. 20 1053–1067.

    Not in our library10.1681/asn.2008070798

  22. 22.

    Bu N. Wu H.-Q. Zhang G.-L. Zhan S.-Q. Zhang R. Fan Q.-Y. (2015 ). Immature dendritic cell exosomes suppress experimental autoimmune myasthenia gravis. J. Neuroimmunol. 285 71–75.

    Not in our library10.1016/j.jneuroim.2015.04.009

  23. 23.

    Buchanan S. S. Gross S. A. Acker J. P. Toner M. Carpenter J. F. Pyatt D. W. (2004 ). Cryopreservation of stem cells using trehalose: evaluation of the method using a human hematopoietic cell line. Stem Cells Dev. 13 295–305.

    Not in our library10.1089/154732804323099226

  24. 24.

    Buchanan S. S. Menze M. A. Hand S. C. Pyatt D. W. Carpenter J. F. (2005 ). Cryopreservation of human hematopoietic stem and progenitor cells loaded with trehalose: transient permeabilization via the adenosine triphosphate-dependent P2Z receptor channel. Cell Preserv. Technol. 3 212–222.

    Not in our library10.1089/cpt.2005.3.212

  25. 25.

    Cantaluppi V. Biancone L. Figliolini F. Beltramo S. Medica D. Deregibus M. C. (2012 ). Microvesicles derived from endothelial progenitor cells enhance neoangiogenesis of human pancreatic islets. Cell Transplant. 21 1305–1320.

    Not in our library10.3727/096368911x627534

  26. 26.

    Cardoso L. M. D. F. Pinto M. A. Henriques Pons A. Alves L. A. (2017 ). Cryopreservation of rat hepatocytes with disaccharides for cell therapy. Cryobiology 78 15–21.

    Not in our library10.1016/j.cryobiol.2017.07.010

  27. 27.

    Carrasco-Ramírez P. Greening D. W. Andrés G. Gopal S. K. Martín-Villar E. Renart J. (2016 ). Podoplanin is a component of extracellular vesicles that reprograms cell-derived exosomal proteins and modulates lymphatic vessel formation. Oncotarget 7 16070–16089.

    Not in our library10.18632/oncotarget.7445

  28. 28.

    Casado-Díaz A. Santiago-Mora R. Jiménez R. Caballero-Villarraso J. Herrera C. Torres A. (2008 ). Cryopreserved human bone marrow mononuclear cells as a source of mesenchymal stromal cells: application in osteoporosis research. Cytotherapy 10 460–468.

    Not in our library10.1080/14653240802192644

  29. 29.

    Chacón M. Molpeceres J. Berges L. Guzmán M. Aberturas M. R. (1999 ). Stability and freeze-drying of cyclosporine loaded poly(D,L-lactide-glycolide) carriers. Eur. J. Pharm. Sci. 8 99–107.

    Not in our library10.1016/s0928-0987(98)00066-9

  30. 30.

    Chan H. K. Clark A. Gonda I. Mumenthaler M. Hsu C. (1997 ). Spray dried powders and powder blends of recombinant human deoxyribonuclease (rhDNase) for aerosol delivery. Pharm. Res. 14 431–437.

    Not in our library10.1023/a:1012035113276

  31. 31.

    Chang Y.-P. Hong H.-P. Lee Y.-H. Liu I.-H. (2015 ). The canine epiphyseal-derived mesenchymal stem cells are comparable to bone marrow derived-mesenchymal stem cells. J. Vet. Med. Sci. 77 273–280.

    Not in our library10.1292/jvms.14-0265

  32. 32.

    Chase L. C. G. Rao M. S. G. Vemuri M. S. (2011 ). Mesenchymal stem cell assays and applications. Methods Mol. Biol. 698 3–8.

    Not in our library10.1007/978-1-60761-999-4

  33. 33.

    Chatzistamatiou T. K. Papassavas A. C. Michalopoulos E. Gamaloutsos C. Mallis P. Gontika I. (2014 ). Optimizing isolation culture and freezing methods to preserve Wharton’s jelly’s mesenchymal stem cell (MSC) properties: an MSC banking protocol validation for the Hellenic Cord Blood Bank. Transfusion 54 3108–3120.

    Not in our library10.1111/trf.12743

  34. 34.

    Chen C. Han D. Cai C. Tang X. (2010 ). An overview of liposome lyophilization and its future potential. J. Control. Release 142 299–311.

    Not in our library10.1016/j.jconrel.2009.10.024

  35. 35.

    Chen G. Yue A. Ruan Z. Yin Y. Wang R. Ren Y. (2016 ). Comparison of the effects of different cryoprotectants on stem cells from umbilical cord blood. Stem Cells Int. 2016:1396783.

    Not in our library10.1155/2016/1396783

  36. 36.
    Effect of pH, temperature and freezing-thawing on quantity changes and cellular uptake of exosomes · 2018
    No notice
  37. 37.

    Choudhery M. S. Badowski M. Muise A. Pierce J. Harris D. T. (2014 ). Cryopreservation of whole adipose tissue for future use in regenerative medicine. J. Surg. Res. 187 24–35.

    Not in our library10.1016/j.jss.2013.09.027

  38. 38.

    Colino J. Snapper C. M. (2006 ). Exosomes from bone marrow dendritic cells pulsed with diphtheria toxoid preferentially induce type 1 antigen-specific IgG responses in naive recipients in the absence of free antigen. J. Immunol. 177 3757–3762.

    Not in our library10.4049/jimmunol.177.6.3757

  39. 39.

    Costantino H. R. Firouzabadian L. Hogeland K. Wu C. Beganski C. Carrasquillo K. G. (2000 ). Protein spray-freeze drying. Effect of atomization conditions on particle size and stability. Pharm. Res. 17 1374–1383.

    Not in our library10.1023/a:1007570030368

  40. 40.

    Crowe J. H. Crowe L. M. Carpenter J. F. Aurell Wistrom C. (1987 ). Stabilization of dry phospholipid bilayers and proteins by sugars. Biochem. J. 242 1–10.

    Not in our library10.1042/bj2420001

  41. 41.

    Cruz F. F. Borg Z. D. Goodwin M. Sokocevic D. Wagner D. E. Coffey A. (2015 ). Systemic administration of human bone marrow-derived mesenchymal stromal cell extracellular vesicles ameliorates aspergillus hyphal extract-induced allergic airway inflammation in immunocompetent mice. Stem Cells Transl. Med. 4 1302–1316.

    Not in our library10.5966/sctm.2014-0280

  42. 42.

    Cui Z. Hsu C. H. Mumper R. J. (2003 ). Physical characterization and macrophage cell uptake of mannan-coated nanoparticles. Drug Dev. Ind. Pharm. 29 689–700.

    Not in our library10.1081/ddc-120021318

  43. 43.

    Dai S. Wei D. Wu Z. Zhou X. Wei X. Huang H. (2008 ). Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. Mol. Ther. 16 782–790.

    Not in our library10.1038/mt.2008.1

  44. 44.

    Damjanovic V. Thomas D. (1974 ). The use of polyvinylpyrrolidone as a cryoprotectant in the freezing of human lymphocytes. Cryobiology 11 312–316.

    Not in our library10.1016/0011-2240(74)90007-8

  45. 45.
    TLR-3 stimulation improves anti-tumor immunity elicited by dendritic cell exosome-based vaccines in a murine model of melanoma · 2015
    No notice
  46. 46.

    Dariolli R. Bassaneze V. Nakamuta J. S. Omae S. V. Campos L. C. G. Krieger J. E. (2013 ). Porcine adipose tissue-derived mesenchymal stem cells retain their proliferative characteristics, senescence, karyotype and plasticity after long-term cryopreservation. PLoS One 8:e67939.

    Not in our library10.1371/journal.pone.0067939

  47. 47.

    Date P. V. Samad A. Devarajan P. V. (2010 ). Freeze thaw: a simple approach for prediction of optimal cryoprotectant for freeze drying. AAPS PharmSciTech 11 304–313.

    Not in our library10.1208/s12249-010-9382-3

  48. 48.

    De Lara Janz F. De Aguiar Debes A. De Cássia Cavaglieri R. Duarte S. A. Romão C. M. Morón A. F. (2012 ). Evaluation of distinct freezing methods and cryoprotectants for human amniotic fluid stem cells cryopreservation. J. Biomed. Biotechnol. 2012:649353.

    Not in our library10.1155/2012/649353

  49. 49.

    Del Fattore A. Luciano R. Pascucci L. Goffredo B. M. Giorda E. Scapaticci M. (2015 ). Immunoregulatory effects of mesenchymal stem cell-derived extracellular vesicles on T lymphocytes. Cell Transplant. 24 2615–2627.

    Not in our library10.3727/096368915x687543

  50. 50.

    Deregibus M. C. Cantaluppi V. Calogero R. Lo Iacono M. Tetta C. Bruno S. (2012 ). Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. Blood 110 2440–2448.

    Not in our library10.1182/blood-2007-03-078709

  51. 51.

    Ding G. Wang W. Liu Y. An Y. Zhang C. Shi S. (2010 ). Effect of cryopreservation on biological and immunological properties of stem cells from apical papilla. J. Cell. Physiol. 223 415–422.

    Not in our library10.1002/jcp.22050

  52. 52.

    Dulugiac M. Moldovan L. Zarnescu O. (2015 ). Comparative studies of mesenchymal stem cells derived from different cord tissue compartments - The influence of cryopreservation and growth media. Placenta 36 1192–1203.

    Not in our library10.1016/j.placenta.2015.08.011

  53. 53.

    Dzieciuch-Rojek M. Poojari C. Bednar J. Bunker A. Kozik B. Nowakowska M. (2017 ). Effects of membrane PEGylation on entry and location of antifungal drug itraconazole and their pharmacological implications. Mol. Pharm. 14 1057–1070.

    Not in our library10.1021/acs.molpharmaceut.6b00969

  54. 54.

    Edamura K. Nakano R. Fujimoto K. Teshima K. Asano K. Tanaka S. (2014 ). Effects of cryopreservation on the cell viability, proliferative capacity and neuronal differentiation potential of canine bone marrow stromal cells. J. Vet. Med. Sci. 76 573–577.

    Not in our library10.1292/jvms.13-0296

  55. 55.

    Eirin A. Zhu X.-Y. Puranik A. S. Tang H. McGurren K. A. van Wijnen A. J. (2017 ). Mesenchymal stem cell-derived extracellular vesicles attenuate kidney inflammation. Kidney Int. 92 114–124.

    Not in our library10.1016/j.kint.2016.12.023

  56. 56.

    El Assal R. Guven S. Gurkan U. A. Gozen I. Shafiee H. Dalbeyler S. (2014 ). Bio-inspired cryo-ink preserves red blood cell phenotype and function during nanoliter vitrification. Adv. Mater. 26 5815–5822.

    Not in our library10.1002/adma.201400941

  57. 57.

    Elliott G. D. Wang S. Fuller B. J. (2017 ). Cryobiology Cryoprotectants: a review of the actions and applications of cryoprotective solutes that modulate cell recovery from ultra-low temperatures. Cryobiology 76 74–91.

    Not in our library10.1016/j.cryobiol.2017.04.004

  58. 58.

    El-Nesr O. H. Yahiya S. A. El-Gazayerly O. N. (2010 ). Effect of formulation design and freeze-drying on properties of fluconazole multilamellar liposomes. Saudi Pharm. J. 18 217–224.

    Not in our library10.1016/j.jsps.2010.07.003

  59. 59.

    Eroglu A. Russo M. J. Bieganski R. Fowler A. Cheley S. Bayley H. (2000 ). Intracellular trehalose improves the survival of cryopreserved mammalian cells. Nat. Biotechnol. 18 163–167.

    Not in our library10.1038/72608

  60. 60.

    Eroglu A. Toner M. Toth T. L. (2002 ). Beneficial effect of microinjected trehalose on the cryosurvival of human oocytes. Fertil. Steril. 77 152–158.

    Not in our library10.1016/s0015-0282(01)02959-4

  61. 61.

    Escola J. M. Kleijmeer M. J. Stoorvogel W. Griffith J. M. Yoshie O. Geuze H. J. (1998 ). Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes. J. Biol. Chem. 273 20121–20127.

    Not in our library10.1074/jbc.273.32.20121

  62. 62.

    Fais S. O’Driscoll L. Borras F. E. Buzas E. Camussi G. Cappello F. (2016 ). Evidence-based clinical use of nanoscale extracellular vesicles in nanomedicine. ACS Nano 10 3886–3899.

    Not in our library10.1021/acsnano.5b08015

  63. 63.

    Favaro E. Carpanetto A. Caorsi C. Giovarelli M. Angelini C. Cavallo-Perin P. (2016 ). Human mesenchymal stem cells and derived extracellular vesicles induce regulatory dendritic cells in type 1 diabetic patients. Diabetologia 59 325–333.

    Not in our library10.1007/s00125-015-3808-0

  64. 64.

    Favaro E. Carpanetto A. Lamorte S. Fusco A. Caorsi C. Deregibus M. C. (2014 ). Human mesenchymal stem cell-derived microvesicles modulate T cell response to islet antigen glutamic acid decarboxylase in patients with type 1 diabetes. Diabetologia 57 1664–1673.

    Not in our library10.1007/s00125-014-3262-4

  65. 65.
    Ischemic Preconditioning Potentiates the Protective Effect of Stem Cells through Secretion of Exosomes by Targeting Mecp2 via miR-22 · 2014
    No notice
  66. 66.

    Fonte P. Soares S. Costa A. Andrade J. C. Seabra V. Reis S. (2012 ). Effect of cryoprotectants on the porosity and stability of insulin-loaded PLGA nanoparticles after freeze-drying. Biomatter 2 329–339.

    Not in our library10.4161/biom.23246

  67. 67.

    Freimark D. Sehl C. Weber C. Hudel K. Czermak P. Hofmann N. (2011 ). Systematic parameter optimization of a Me2SO- and serum-free cryopreservation protocol for human mesenchymal stem cells. Cryobiology 63 67–75.

    Not in our library10.1016/j.cryobiol.2011.05.002

  68. 68.

    Gala R. P. Khan I. Elhissi A. M. A. Alhnan M. A. (2015 ). A comprehensive production method of self-cryoprotected nano-liposome powders. Int. J. Pharm. 486 153–158.

    Not in our library10.1016/j.ijpharm.2015.03.038

  69. 69.
    miRNA in Plasma Exosome is Stable under Different Storage Conditions · 2014
    No notice
  70. 70.

    Gnecchi M. Danieli P. Malpasso G. Ciuffreda M. C. (2016 ). “Paracrine mechanisms of mesenchymal stem cells in tissue repair,” in Mesenchymal Stem Cells: Methods and Protocols, ed. Gnecchi M. (New York, NY: Springer), 123–146.

    Not in our library10.1007/978-1-4939-3584-0_7

  71. 71.

    Ha S. Y. Jee B. C. Suh C. S. Kim H. S. Oh S. K. Kim S. H. (2005 ). Cryopreservation of human embryonic stem cells without the use of a programmable freezer. Hum. Reprod. 20 1779–1785.

    Not in our library10.1093/humrep/deh854

  72. 72.

    Hansen L. J. J. Daoussi R. Vervaet C. Remon J. -P. De Beer T. R. M. (2015 ). Freeze-drying of live virus vaccines: a review. Vaccine 33 5507–5519.

    Not in our library10.1016/j.vaccine.2015.08.085

  73. 73.

    Harrigan P. R. Madden T. D. Cullis P. R. (1990 ). Protection of liposomes during dehydration or freezing. Chem. Phys. Lipids 52 139–149.

    Not in our library10.1016/0009-3084(90)90157-m

  74. 74.

    Hasan A. (2017 ). Tissue Engineering for Artificial Organs. Available at: https://onlinelibrary.wiley.com/doi/book/10.1002/9783527689934

    Not in our library

  75. 75.

    Hau Z. Z. Li B. G. Liu Z. J. Sun D. W. (2003 ). Freeze-drying of liposomes with cryoprotectants and its effect on retention rate of encapsulated ftorafur and vitamin A. Dry. Technol. 21 1491–1505.

    Not in our library10.1081/drt-120024489

  76. 76.

    Heinrich U. Garbe B. Tronnier H. (2007 ). In vivo assessment of ectoin: a randomized, vehicle-controlled clinical trial. Skin Pharmacol. Physiol. 20 211–218.

    Not in our library10.1159/000103204

  77. 77.

    Hendriks J. Riesle J. van Blitterswijk C. A. (2010 ). Co-culture in cartilage tissue engineering. J. Tissue Eng. Regen. Med. 4 524–531.

    Not in our library10.1002/term

  78. 78.

    Hergenreider E. Heydt S. Treguer K. Boettger T. Horrevoets A. J. G. Zeiher A. M. (2012 ). Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nat. Cell Biol. 14 249–256.

    Not in our library10.1038/ncb2441

  79. 79.

    Hewson C. Capraro D. Burdach J. Whitaker N. Morris K. V. (2016 ). Extracellular vesicle associated long non-coding RNAs functionally enhance cell viability. Noncoding RNA Res. 1 3–11.

    Not in our library10.1016/j.ncrna.2016.06.001

  80. 80.

    Hood J. L. Scott M. J. Wickline S. A. (2014 ). Maximizing exosome colloidal stability following electroporation. Anal. Biochem. 448 41–49.

    Not in our library10.1016/j.ab.2013.12.001

  81. 81.
    Exosomes secreted by human-induced pluripotent stem cell-derived mesenchymal stem cells attenuate limb ischemia by promoting angiogenesis in mice · 2015
    No notice
  82. 82.
    Exosomes derived from human adipose mensenchymal stem cells accelerates cutaneous wound healing via optimizing the characteristics of fibroblasts · 2016
    Corrected
  83. 83.

    Hu Y. Rao S.-S. Wang Z.-X. Cao J. Tan Y.-J. Luo J. (2018 ). Exosomes from human umbilical cord blood accelerate cutaneous wound healing through miR-21-3p-mediated promotion of angiogenesis and fibroblast function. Theranostics 8 169–184.

    Not in our library10.7150/thno.21234

  84. 84.

    Huang H. Choi J. K. Rao W. Zhao S. Agarwal P. Zhao G. (2015 ). Alginate hydrogel microencapsulation inhibits devitrification and enables large-volume low-CPA cell vitrification. Adv. Funct. Mater. 25 6839–6850.

    Not in our library10.1002/adfm.201503047

  85. 85.

    Huleihel L. Hussey G. S. Naranjo J. D. Zhang L. Dziki J. L. Turner N. J. (2016 ). Matrix-bound nanovesicles within ECM bioscaffolds. Sci. Adv. 2:e1600502.

    Not in our library10.1126/sciadv.1600502

  86. 86.

    Ibrahim A. G. Cheng K. Marban E. (2014 ). Exosomes as critical agents of cardiac regeneration triggered by cell therapy. Stem Cell Rep. 2 606–619.

    Not in our library10.1016/j.stemcr.2014.04.006

  87. 87.

    Iglesias D. M. El-Kares R. Taranta A. Bellomo F. Emma F. Besouw M. (2012 ). Stem cell microvesicles transfer cystinosin to human cystinotic cells and reduce cystine accumulation in vitro. PLoS One 7:e42840.

    Not in our library10.1371/journal.pone.0042840

  88. 88.

    Jain N. K. Roy I. (2009 ). Effect of trehalose on protein structure. Protein Sci. 18 24–36.

    Not in our library10.1002/pro.3

  89. 89.

    Jan D. B. Van Blitterswijk C. Thomsen P. Hubbell J. Cancedda R. de Bruijn J. D. Lindahl A. (2008 ). Tissue Engineering. Amsterdam: Elsevier, 369.

    Not in our library

  90. 90.

    Jong A. Y. Wu C. H. Li J. Sun J. Fabbri M. Wayne A. S. (2017 ). Large-scale isolation and cytotoxicity of extracellular vesicles derived from activated human natural killer cells. J. Extracell. Vesicles 6:1294368.

    Not in our library10.1080/20013078.2017.1294368

  91. 91.
    Focus on Extracellular Vesicles: Introducing the Next Small Big Thing · 2016
    No notice
  92. 92.

    Kang Y.-S. Jung H.-J. Oh J.-S. Song D.-Y. (2016 ). Use of PEGylated immunoliposomes to deliver dopamine across the blood-brain barrier in a rat model of parkinson’s disease. CNS Neurosci. Ther. 22 817–823.

    Not in our library10.1111/cns.12580

  93. 93.

    Katenz E. Vondran F. W. Schwartlander R. Pless G. Gong X. Cheng X. Neuhaus P. (2007 ). Cryopreservation of primary human hepatocytes: the benefit of trehalose as an additional cryoprotective agent. Liver Transplant. 13 465–466.

    Not in our library10.1002/lt

  94. 94.

    Katsuda T. Tsuchiya R. Kosaka N. Yoshioka Y. Takagaki K. Oki K. (2013 ). Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes. Sci. Rep. 3:1197.

    Not in our library10.1038/srep01197

  95. 95.

    Kaviani M. Ezzatabadipour M. Nematollahi-Mahani S. N. Salehinejad P. Mohammadi M. Kalantar S. M. (2014 ). Evaluation of gametogenic potential of vitrified human umbilical cord Wharton’s jelly-derived mesenchymal cells. Cytotherapy 16 203–212.

    Not in our library10.1016/j.jcyt.2013.10.015

  96. 96.

    Ke X. Yang D. Liang J. Wang X. Wu S. Wang X. (2017 ). Human endothelial progenitor cell-derived exosomes increase proliferation and angiogenesis in cardiac fibroblasts by promoting the mesenchymal–endothelial transition and reducing high mobility group box 1 protein B1 expression. DNA Cell Biol. 36 1018–1028.

    Not in our library10.1089/dna.2017.3836

  97. 97.

    Keerthikumar S. Chisanga D. Ariyaratne D. Al Saffar H. Anand S. Zhao K. (2016 ). ExoCarta: a web-based compendium of exosomal cargo. J. Mol. Biol. 428 688–692.

    Not in our library10.1016/j.jmb.2015.09.019

  98. 98.

    Kesenci K. Motta A. Fambri L. (2001 ). Poly(ε-caprolactone-co-D, L-lactide)/silk fibroin composite materials: preparation and characterization. J. Biomater. Sci. Polym. Ed. 12 337–351.

    Not in our library10.1016/s0939

  99. 99.

    Khairnar S. Kini R. Harwalker M. Slaunkhe K. Chaudhari S. (2013 ). A review on freeze drying process and pharmaceuticals. Int. J. Res. Pharm. Sci. 4 76–94.

    Not in our library

  100. 100.

    Khatua A. K. Taylor H. E. Hildreth J. E. K. Popik W. (2009 ). Exosomes packaging APOBEC3G confer human immunodeficiency virus resistance to recipient cells. J. Virol. 83 512–521.

    Not in our library10.1128/jvi.01658-08

  101. 101.

    Kim C.-G. Yong H. Lee G. Cho J. (2008 ). Effect of the polyvinylpyrrolidone concentration of cryoprotectant on mouse embryo development and production of pups: 7.5% of PVP is beneficial for in vitro and in vivo development of frozen-thawed mouse embryos. J. Reprod. Dev. 54 250–253.

    Not in our library10.1262/jrd.19185

  102. 102.

    Kordelas L. Rebmann V. Ludwig A.-K. Radtke S. Ruesing J. Doeppner T. R. (2014 ). MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease. Leukemia 28 970–973.

    Not in our library10.1038/leu.2014.41

  103. 103.

    Kotobuki N. Hirose M. Machida H. Katou Y. Muraki K. Takakura Y. (2005 ). Viability and osteogenic potential of cryopreserved human bone marrow-derived mesenchymal cells. Tissue Eng. 11 663–673.

    Not in our library10.1089/ten.2005.11.663

  104. 104.

    Kreke M. Smith R. Hanscome P. Peck K. Ibrahim A. (2016 ). Processes for producing stable exosome formulations. U.S. Patent No 14/958,804.

    Not in our library

  105. 105.
    Shielding of Lipid Nanoparticles for siRNA Delivery: Impact on Physicochemical Properties, Cytokine Induction, and Efficacy · 2014
    No notice
  106. 106.

    Kusuma G. D. Carthew J. Lim R. Frith J. E. (2017 ). Effect of the microenvironment on mesenchymal stem cells paracrine signalling: opportunities to engineer the therapeutic effect. Stem Cells Dev. 26 617–631.

    Not in our library10.1089/scd.2016.0349

  107. 107.

    Laulagnier K. Motta C. Hamdi S. Roy S. Fauvelle F. Pageaux J.-F. (2004 ). Mast cell- and dendritic cell-derived exosomes display a specific lipid composition and an unusual membrane organization. Biochem. J. 380 161–171.

    Not in our library10.1042/bj20031594

  108. 108.

    Lee G. (2002 ). Spray-drying of proteins. Pharm. Biotechnol. 13 135–158.

    Not in our library10.1007/978-1-4615-0557-0_6

  109. 109.

    Lee J. (2014 ). Trehalose Glycopolymers and Hydrogels for Enhancing Protein Stability. Doctoral dissertation, Los Angeles, CA, Regents of the University of California.

    Not in our library

  110. 110.

    Lee M. Ban J. J. Im W. Kim M. (2016 ). Influence of storage condition on exosome recovery. Biotechnol. Bioprocess Eng. 21 299–304.

    Not in our library10.1007/s12257-015-0781-x

  111. 111.
    Applying extracellular vesicles based therapeutics in clinical trials – an ISEV position paper · 2015
    Not checked
  112. 112.

    Li J. Zhang Y. Liu Y. Dai X. Li W. Cai X. (2013 ). Microvesicle-mediated transfer of microRNA-150 from monocytes to endothelial cells promotes angiogenesis. J. Biol. Chem. 288 23586–23596.

    Not in our library10.1074/jbc.m113.489302

  113. 113.

    Li X. Jiang C. Zhao J. (2016 ). Human endothelial progenitor cells-derived exosomes accelerate cutaneous wound healing in diabetic rats by promoting endothelial function. J. Diabetes Complications 30 986–992.

    Not in our library10.1016/j.jdiacomp.2016.05.009

  114. 114.

    Liang X. Zhang L. Wang S. Han Q. Zhao R. C. (2016 ). Exosomes secreted by mesenchymal stem cells promote endothelial cell angiogenesis by transferring miR-125a. J. Cell Sci. 129 2182–2189.

    Not in our library10.1242/jcs.170373

  115. 115.

    Lindemann D. Werle S. B. Steffens D. Garcia-Godoy F. Pranke P. Casagrande L. (2014 ). Effects of cryopreservation on the characteristics of dental pulp stem cells of intact deciduous teeth. Arch. Oral Biol. 59 970–976.

    Not in our library10.1016/j.archoralbio.2014.04.008

  116. 116.

    Lindoso R. S. Collino F. Bruno S. Araujo D. S. Sant’Anna J. F. Tetta C. (2014 ). Extracellular vesicles released from mesenchymal stromal cells modulate miRNA in renal tubular cells and inhibit ATP depletion injury. Stem Cells Dev. 23 1809–1819.

    Not in our library10.1089/scd.2013.0618

  117. 117.

    Liu S. Liu D. Chen C. Hamamura K. Moshaverinia A. Yang R. (2015 ). MSC transplantation improves osteopenia via epigenetic regulation of notch signaling in lupus. Cell Metab. 22 606–618.

    Not in our library10.1016/j.cmet.2015.08.018

  118. 118.
    Effect of storage on physical and functional properties of extracellular vesicles derived from neutrophilic granulocytes · 2014
    Not checked
  119. 119.

    Lötvall J. Hill A. F. Hochberg F. Buzás E. I. Di Vizio D. Gardiner C. (2014 ). Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. J. Extracell. Vesicles 3:26913.

    Not in our library10.3402/jev.v3.26913

  120. 120.
    Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma · 2015
    No notice
  121. 121.

    Lv L. L. Cao Y. Liu D. Xu M. Liu H. Tang R. N. (2013 ). Isolation and quantification of MicroRNAs from urinary exosomes/microvesicles for biomarker discovery. Int. J. Biol. Sci. 9 1021–1031.

    Not in our library10.7150/ijbs.6100

  122. 122.

    Lydic T. A. Townsend S. Adda C. G. Collins C. Mathivanan S. Reid G. E. (2015 ). Rapid and comprehensive “shotgun” lipidome profiling of colorectal cancer cell derived exosomes. Methods 87 83–95.

    Not in our library10.1016/j.ymeth.2015.04.014

  123. 123.

    Manconi M. Manca M. L. Valenti D. Escribano E. Hillaireau H. Fadda A. M. (2017 ). Chitosan and hyaluronan coated liposomes for pulmonary administration of curcumin. Int. J. Pharm. 525 203–210.

    Not in our library10.1016/j.ijpharm.2017.04.044

  124. 124.

    Maroto R. Zhao Y. Jamaluddin M. Popov V. L. Wang H. Kalubowilage M. (2017 ). Effects of storage temperature on airway exosome integrity for diagnostic and functional analyses. J. Extracell. Vesicles 6:1359478.

    Not in our library10.1080/20013078.2017.1359478

  125. 125.

    Marquez-Curtis L. A. Janowska-Wieczorek A. McGann L. E. Elliott J. A. W. (2015 ). Mesenchymal stromal cells derived from various tissues: biological, clinical and cryopreservation aspects. Cryobiology 71 181–197.

    Not in our library10.1016/j.cryobiol.2015.07.003

  126. 126.

    Martinello T. Bronzini I. Maccatrozzo L. Iacopetti I. Sampaolesi M. Mascarello F. (2010 ). Cryopreservation does not affect the stem characteristics of multipotent cells isolated from equine peripheral blood. Tissue Eng. Part C Methods 16 771–781.

    Not in our library10.1089/ten.tec.2009.0512

  127. 127.

    Martinetti D. Colarossi C. Buccheri S. Denti G. Memeo L. Vicari L. (2017 ). Effect of trehalose on cryopreservation of pure peripheral blood stem cells. Biomed. Rep. 6 314–318.

    Not in our library10.3892/br.2017.859

  128. 128.

    Masters K. (1972 ). Spray Drying: an Introduction to Principles, Operational Practice, and Applications /K. Masters. London: G. Godwin.

    Not in our library

  129. 129.

    Mayourian J. Ceholski D. K. Gorski P. Mathiyalagan P. Murphy J. F. Salazar S. I. (2018 ). Exosomal microRNA-21-5p mediates mesenchymal stem cell paracrine effects on human cardiac tissue contractility. Circ. Res. 122 933–944.

    Not in our library10.1161/circresaha.118.312420

  130. 130.

    Monsel A. Zhu Y. Gennai S. Hao Q. Hu S. Rouby J.-J. (2015 ). Therapeutic effects of human mesenchymal stem cell-derived microvesicles in severe pneumonia in mice. Am. J. Respir. Crit. Care Med. 192 324–336.

    Not in our library10.1164/rccm.201410-1765oc

  131. 131.

    Moon J. H. Lee J. R. Jee B. C. Suh C. S. Kim S. H. Lim H. J. (2008 ). Successful vitrification of human amnion-derived mesenchymal stem cells. Hum. Reprod. 23 1760–1770.

    Not in our library10.1093/humrep/den202

  132. 132.
    A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer · 2005
    No notice
  133. 133.

    Motta J. P. R. Paraguassú-Braga F. H. Bouzas L. F. Porto L. C. (2014 ). Evaluation of intracellular and extracellular trehalose as a cryoprotectant of stem cells obtained from umbilical cord blood. Cryobiology 68 343–348.

    Not in our library10.1016/j.cryobiol.2014.04.007

  134. 134.

    Naaldijk Y. Staude M. Fedorova V. Stolzing A. (2012 ). Effect of different freezing rates during cryopreservation of rat mesenchymal stem cells using combinations of hydroxyethyl starch and dimethylsulfoxide. BMC Biotechnol. 12:49.

    Not in our library10.1186/1472-6750-12-49

  135. 135.

    Nam B. M. Kim B. Y. Jo Y. H. Lee S. Nemeno J. G. Yang W. (2014 ). Effect of cryopreservation and cell passage number on cell preparations destined for autologous chondrocyte transplantation. Transplant. Proc. 46 1145–1149.

    Not in our library10.1016/j.transproceed.2013.11.117

  136. 136.
    Hijacking the Cellular Mail: Exosome Mediated Differentiation of Mesenchymal Stem Cells · 2016
    No notice
  137. 137.

    Naslund T. I. Gehrmann U. Qazi K. R. Karlsson M. C. I. Gabrielsson S. (2013 ). Dendritic cell-derived exosomes need to activate both T and B cells to induce antitumor immunity. J. Immunol. 190 2712–2719.

    Not in our library10.4049/jimmunol.1203082

  138. 138.

    Nidhi K. Indrajeet S. Khushboo M. Gauri K. Sen D. J. (2011 ). Hydrotropy: a promising tool for solubility enhancement: a review. Int. J. Drug Dev. Res. 3 26–33.

    Not in our library10.1002/jps

  139. 139.

    Nounou M. El-Khordagui L. (2005 ). Influence of different sugar cryoprotectants on the stability and physico-chemical characteristics of freeze-dried 5-fluorouracil plurilamellar vesicles. DARU J. Pharm. Sci. 13 133–142.

    Not in our library

  140. 140.

    Ono M. Kosaka N. Tominaga N. Yoshioka Y. Takeshita F. Takahashi R. U. (2014 ). Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells. Sci. Signal. 7:ra63.

    Not in our library10.1126/scisignal.2005231

  141. 141.
    Mesenchymal Stromal Cell‐Derived Extracellular Vesicles Protect the Fetal Brain After Hypoxia‐Ischemia · 2016
    Not checked
  142. 142.

    Pachler K. Lener T. Streif D. Dunai Z. A. Desgeorges A. Feichtner M. (2017 ). A Good Manufacturing Practice–grade standard protocol for exclusively human mesenchymal stromal cell–derived extracellular vesicles. Cytotherapy 19 458–472.

    Not in our library10.1016/j.jcyt.2017.01.001

  143. 143.

    Pakravan K. Babashah S. Sadeghizadeh M. Mowla S. J. Mossahebi-Mohammadi M. Ataei F. (2017 ). MicroRNA-100 shuttled by mesenchymal stem cell-derived exosomes suppresses in vitro angiogenesis through modulating the mTOR/HIF-1α/VEGF signaling axis in breast cancer cells. Cell. Oncol. 40 457–470.

    Not in our library10.1007/s13402-017-0335-7

  144. 144.

    Panyam J. Labhasetwar V. (2012 ). Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 64 61–71.

    Not in our library10.1016/j.addr.2012.09.023

  145. 145.

    Patel A. R. Patel D. A. Chaudhry S. V. (2011 ). Mucoadhesive buccal drug delivery system. Int. J. Pharm. Life Sci. 2 848–856.

    Not in our library

  146. 146.

    Pemberton T. A. Still B. R. Christensen E. M. Singh H. Srivastava D. Tanner J. J. (2012 ). Proline: mother Natures cryoprotectant applied to protein crystallography. Acta Crystallogr. Sect. D Biol. Crystallogr. 68 1010–1018.

    Not in our library10.1107/s0907444912019580

  147. 147.
    Mesenchymal stem cells use extracellular vesicles to outsource mitophagy and shuttle microRNAs · 2015
    No notice
  148. 148.

    Pironti G. Strachan R. T. Abraham D. Mon-Wei Yu S. Chen M. Chen W. (2015 ). Circulating exosomes induced by cardiac pressure overload contain functional angiotensin II type 1 receptors. Circulation 131 2120–2130.

    Not in our library10.1161/circulationaha.115.015687

  149. 149.

    Pusic A. D. Pusic K. M. Clayton B. L. L. Kraig R. P. (2014 ). IFNgamma-stimulated dendritic cell exosomes as a potential therapeutic for remyelination. J. Neuroimmunol. 266 12–23.

    Not in our library10.1016/j.jneuroim.2013.10.014

  150. 150.
    Bone marrow stromal/stem cell-derived extracellular vesicles regulate osteoblast activity and differentiation in vitro and promote bone regeneration in vivo · 2016
    No notice
  151. 151.

    Quintanar-Guerrero D. Ganem-Quintanar A. Allémann E. Fessi H. Doelker E. (1998 ). Influence of the stabilizer coating layer on the purification and freeze-drying of poly(D,L-lactic acid) nanoparticles prepared by an emulsion-diffusion technique. J. Microencapsul. 15 107–119.

    Not in our library10.3109/02652049809006840

  152. 152.

    Ragni E. Banfi F. Barilani M. Cherubini A. Parazzi V. Larghi P. (2016 ). Extracellular vesicle-shuttled mRNA in mesenchymal stem cell communication. Stem Cells 35 1093–1105.

    Not in our library10.1002/stem.2557

  153. 153.

    Rana S. Zoller M. (2013 ). “The functional importance of tetraspanins in exosomes,” in Emerging Concepts of Tumor Exosome-Mediated Cell-Cell Communication, ed. Zhang H.-G. (Berlin: Springer Science+Business Media), 69–106.

    Not in our library10.1007/978-1-4614-3697-3

  154. 154.

    Rao W. Huang H. Wang H. Zhao S. Dumbleton J. Zhao G. (2015 ). Nanoparticle-mediated intracellular delivery enables cryopreservation of human adipose-derived stem cells using trehalose as the sole cryoprotectant. ACS Appl. Mater. Interfaces 7 5017–5028.

    Not in our library10.1021/acsami.5b00655

  155. 155.

    Raposo G. Stoorvogel W. (2013 ). Extracellular vesicles: exosomes, microvesicles, and friends. J. Cell Biol. 200 373–383.

    Not in our library10.1083/jcb.201211138

  156. 156.

    Ray S. S. Pramanik K. Sarangi S. K. Jain N. (2016 ). Serum-free non-toxic freezing solution for cryopreservation of human adipose tissue-derived mesenchymal stem cells. Biotechnol. Lett. 38 1397–1404.

    Not in our library10.1007/s10529-016-2111-6

  157. 157.

    Roy D. Guillon X. Lescure F. Couvreur P. Bru N. Breton P. (1997 ). On shelf stability of freeze-dried: poly(methylidene malonate 2.1.2) nanoparticles. Int. J. Pharm. 148 165–175.

    Not in our library10.1016/s0378-5173(96)04842-9

  158. 158.

    Roy S. Arora S. Kumari P. Ta M. (2014 ). A simple and serum-free protocol for cryopreservation of human umbilical cord as source of Wharton’s jelly mesenchymal stem cells. Cryobiology 68 467–472.

    Not in our library10.1016/j.cryobiol.2014.03.010

  159. 159.

    Rubenfeld G. D. Caldwell E. Peabody E. Weaver J. Martin D. P. Neff M. (2005 ). Incidence and outcomes of acute lung injury. N. Engl. J. Med. 353 1685–1693.

    Not in our library10.1056/nejmoa050333

  160. 160.

    Rust P. A. Tingerides C. Cannon S. R. Briggs T. W. R. Blunn G. W. (2006 ). Characterisation of cryopreserved cells freshly isolated from human bone marrow. Cryo Lett. 27 17–28.

    Not in our library

  161. 161.

    Salama R. O. Traini D. Chan H.-K. Sung A. Ammit A. J. Young P. M. (2009 ). Preparation and evaluation of controlled release microparticles for respiratory protein therapy. J. Pharm. Sci. 98 2709–2717.

    Not in our library10.1002/jps.21653

  162. 162.

    Sameti M. Bohr G. Ravi Kumar M. N. V. Kneuer C. Bakowsky U. Nacken M. (2003 ). Stabilisation by freeze-drying of cationically modified silica nanoparticles for gene delivery. Int. J. Pharm. 266 51–60.

    Not in our library10.1016/s0378-5173(03)00380-6

  163. 163.

    Schaffazick S. R. Pohlmann A. R. Dalla-Costa T. Guterres S. S. (2003 ). Freeze-drying polymeric colloidal suspensions: nanocapsules, nanospheres and nanodispersion. A comparative study. Eur. J. Pharm. Biopharm. 56 501–505.

    Not in our library10.1016/s0939-6411(03)00139-5

  164. 164.

    Schwarz C. Mehnert W. (1997 ). Freeze-drying of drug-free and drug-loaded solid lipid nanoparticles ( SLN ). Int. J. Pharm. 157 171–179.

    Not in our library10.1016/s0378-5173(97)00222-6

  165. 165.

    Sehgal S. Rogers J. A. (1995 ). Polymer-coated liposomes: improved liposome stability and release of cytosine arabinoside (Ara-C). J. Microencapsul. 12 37–47.

    Not in our library10.3109/02652049509051125

  166. 166.

    Shapiro I. M. Landis W. J. Risbud M. V. (2015 ). Matrix vesicles: are they anchored exosomes? Bone 79 29–36.

    Not in our library10.1016/j.bone.2015.05.013

  167. 167.

    Sheldon H. Heikamp E. Turley H. Dragovic R. Thomas P. Oon C. E. (2010 ). New mechanism for Notch signaling to endothelium at a distance by delta-like 4 incorporation into exosomes. Blood 116 2385–2394.

    Not in our library10.1182/blood-2009-08-239228

  168. 168.

    Shen J. L. Huang Y. Z. Xu S. X. Zheng P. H. Yin W. J. Cen J. (2012 ). Effectiveness of human mesenchymal stem cells derived from bone marrow cryopreserved for 23-25 years. Cryobiology 64 167–175.

    Not in our library10.1016/j.cryobiol.2012.01.004

  169. 169.
    GMSC-Derived Exosomes Combined with a Chitosan/Silk Hydrogel Sponge Accelerates Wound Healing in a Diabetic Rat Skin Defect Model · 2017
    No notice
  170. 170.

    Shigemoto-Kuroda T. Oh J. Y. Kim D.-K. Jeong H. J. Park S. Y. Lee H. J. (2017 ). MSC-derived extracellular vesicles attenuate immune responses in two autoimmune murine models: type 1 diabetes and uveoretinitis. Stem Cell Rep. 8 1214–1225.

    Not in our library10.1016/j.stemcr.2017.04.008

  171. 171.

    Shivakumar S. B. Bharti D. Jang S. J. Hwang S. C. Park J. K. Shin J. K. (2015 ). Cryopreservation of human wharton’s jelly-derived mesenchymal stem cells following controlled rate freezing protocol using different cryoprotectants; a comparative study. Int. J. Stem Cells 8 155–169.

    Not in our library10.15283/ijsc.2015.8.2.155

  172. 172.

    Skotland T. Sandvig K. Llorente A. (2017 ). Lipids in exosomes: current knowledge and the way forward. Prog. Lipid Res. 66 30–41.

    Not in our library10.1016/j.plipres.2017.03.001

  173. 173.

    Sokolova V. Ludwig A. Hornung S. Rotan O. Horn P. A. Epple M. (2011 ). Colloids and surfaces B: biointerfaces Characterisation of exosomes derived from human cells by nanoparticle tracking analysis and scanning electron microscopy. Colloids Surf. B Biointerfaces 87 146–150.

    Not in our library10.1016/j.colsurfb.2011.05.013

  174. 174.

    Song Y. Dou H. Li X. Zhao X. Li Y. Liu D. (2017 ). Exosomal miR-146a contributes to the enhanced therapeutic efficacy of IL-1β-primed mesenchymal stem cells against sepsis. Stem Cells 35 1208–1221.

    Not in our library10.1002/stem.2564

  175. 175.

    Stamer W. D. Hoffman E. A. Luther J. M. Hachey D. L. Schey K. L. (2011 ). Protein profile of exosomes from trabecular meshwork cells. J. Proteomics 74 796–804.

    Not in our library10.1016/j.jprot.2011.02.024

  176. 176.

    Stark B. Pabst G. Prassl R. (2010 ). Long-term stability of sterically stabilized liposomes by freezing and freeze-drying: effects of cryoprotectants on structure. Eur. J. Pharm. Sci. 41 546–555.

    Not in our library10.1016/j.ejps.2010.08.010

  177. 177.

    Stolzenburg L. R. Harris A. (2017 ). Microvesicle-mediated delivery of miR-1343: impact on markers of fibrosis. Cell Tissue Res. 371 325–338.

    Not in our library10.1007/s00441-017-2697-6

  178. 178.

    Storm G. Belliot S. O. Daemen T. Lasic D. D. (1995 ). Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv. Drug Deliv. Rev. 17 31–48.

    Not in our library10.1016/0169-409x(95)00039-a

  179. 179.

    Subedi R. K. Kang K. W. Choi H. K. (2009 ). Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin. Eur. J. Pharm. Sci. 37 508–513.

    Not in our library10.1016/j.ejps.2009.04.008

  180. 180.

    Subra C. Laulagnier K. Perret B. Record M. (2007 ). Exosome lipidomics unravels lipid sorting at the level of multivesicular bodies. Biochimie 89 205–212.

    Not in our library10.1016/j.biochi.2006.10.014

  181. 181.

    Sudres M. Maurer M. Robinet M. Bismuth J. Truffault F. Girard D. (2017 ). Preconditioned mesenchymal stem cells treat myasthenia gravis in a humanized preclinical model. JCI Insight 2:e89665.

    Not in our library10.1172/jci.insight.89665

  182. 182.

    Sun H. Glasmacher B. Hofmann N. (2012 ). Compatible solutes improve cryopreservation of human endothelial cells. Cryo Lett. 33 485–493.

    Not in our library

  183. 183.

    Takeuchi H. Kojima H. Yamamoto H. Kawashima Y. (2000 ). Polymer coating of liposomes with a modified polyvinyl alcohol and their systemic circulation and RES uptake in rats. J. Control. Release 68 195–205.

    Not in our library10.1016/s0168-3659(00)00260-1

  184. 184.
    Mesenchymal stem cell-derived exosomes promote hepatic regeneration in drug-induced liver injury models · 2014
    No notice
  185. 185.

    Tan J. L. Lau S. N. Leaw B. Nguyen H. P. T. Salamonsen L. A. Saad M. I. (2018 ). Amnion epithelial cell-derived exosomes restrict lung injury and enhance endogenous lung repair. Stem Cells Transl. Med. 7 180–196.

    Not in our library10.1002/sctm.17-0185

  186. 186.

    Tanaka K. Kawamura M. Otake K. Toiyama Y. Okugawa Y. Inoue Y. (2014 ). Trehalose does not affect the functions of human neutrophils in vitro. Surg. Today 44 332–339.

    Not in our library10.1007/s00595-013-0625-2

  187. 187.

    Thery C. Boussac M. Veron P. Ricciardi-Castagnoli P. Raposo G. Garin J. (2001 ). Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. J. Immunol. 166 7309–7318.

    Not in our library10.4049/jimmunol.166.12.7309

  188. 188.

    Thery C. Regnault A. Garin J. Wolfers J. Zitvogel L. Ricciardi-Castagnoli P. (1999 ). Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73. J. Cell Biol. 147 599–610.

    Not in our library10.1083/jcb.147.3.599

  189. 189.

    Thirumala S. Gimble J. M. Devireddy R. V. (2010 ). Evaluation of methylcellulose and dimethyl sulfoxide as the cryoprotectants in a serum-free freezing media for cryopreservation of adipose-derived adult stem cells. Stem Cells Dev. 19 513–522.

    Not in our library10.1089/scd.2009.0173

  190. 190.

    Tian Y. Li S. Song J. Ji T. Zhu M. Anderson G. J. (2014 ). A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials 35 2383–2390.

    Not in our library10.1016/j.biomaterials.2013.11.083

  191. 191.

    Tkach M. Théry C. (2016 ). Communication by extracellular vesicles: where we are and where we need to go. Cell 164 1226–1232.

    Not in our library10.1016/j.cell.2016.01.043

  192. 192.

    Tomasoni S. Longaretti L. Rota C. Morigi M. Conti S. Gotti E. (2013 ). Transfer of growth factor receptor mRNA via exosomes unravels the regenerative effect of mesenchymal stem cells. Stem Cells Dev. 22 772–780.

    Not in our library10.1089/scd.2012.0266

  193. 193.

    Trad F. S. Toner M. Biggers J. D. (1999 ). Effects of cryoprotectants and ice-seeding temperature on intracellular freezing and survival of human oocytes. Hum. Reprod. 14 1569–1577.

    Not in our library10.1093/humrep/14.6.1569

  194. 194.

    Valadi H. Ekström K. Bossios A. Sjöstrand M. Lee J. J. Lötvall J. O. (2007 ). Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9 654–659.

    Not in our library10.1038/ncb1596

  195. 195.
    Extracellular vesicles from bone marrow mesenchymal stem/stromal cells transport tumor regulatory microRNA, proteins, and metabolites · 2014
    No notice
  196. 196.

    Van Backstal P.-J. De Beer T. Corver J. (2017 ). A continuous and controlled pharmaceutical freeze-drying technology for unit doses. Eur. Pharm. Rev. 22 51–53.

    Not in our library10.1016/j.ijpharm.2018.02.003

  197. 197.

    van Niel G. D’Angelo G. Raposo G. (2018 ). Shedding light on the cell biology of extracellular vesicles. Nat. Rev. Mol. Cell Biol. 19 213–228.

    Not in our library10.1038/nrm.2017.125

  198. 198.

    van Niel G. Porto-Carreiro I. Simoes S. Raposo G. (2006 ). Exosomes: a common pathway for a specialized function. J. Biochem. 140 13–21.

    Not in our library10.1093/jb/mvj128

  199. 199.
    Dendritic Cell-Derived Exosomes Promote Natural Killer Cell Activation and Proliferation: A Role for NKG2D Ligands and IL-15Rα · 2009
    No notice
  200. 200.

    Vrijsen K. R. Maring J. A. Chamuleau S. A. J. Verhage V. Mol E. A. Deddens J. C. (2016 ). Exosomes from cardiomyocyte progenitor cells and mesenchymal stem cells stimulate angiogenesis via EMMPRIN. Adv. Healthc. Mater. 5 2555–2565.

    Not in our library10.1002/adhm.201600308

  201. 201.

    Wang B. Yao K. Huuskes B. M. Shen H. -H. Zhuang J. Godson C. (2016 ). Mesenchymal stem cells deliver exogenous MicroRNA-let7c via exosomes to attenuate renal fibrosis. Mol. Ther. 24 1290–1301.

    Not in our library10.1038/mt.2016.90

  202. 202.

    Wang H.-Y. Lun Z.-R. Lu S.-S. (2011 ). Cryopreservation of umbilical cord blood-derived mesenchymal stem cells without dimethyl sulfoxide. Cryo Lett. 32 81–88.

    Not in our library

  203. 203.

    Wang Y. Zhang L. Li Y. Chen L. Wang X. Guo W. (2015 ). Exosomes/microvesicles from induced pluripotent stem cells deliver cardioprotective miRNAs and prevent cardiomyocyte apoptosis in the ischemic myocardium. Int. J. Cardiol. 192 61–69.

    Not in our library10.1016/j.ijcard.2015.05.020

  204. 204.

    Willison J. H. M. Rowe A. J. (1980 ). Replica, Shadowing and Freeze-Etching Techniques. Amsterdam: Elsevier.

    Not in our library

  205. 205.

    Woods E. J. Perry B. C. Hockema J. J. Larson L. Zhou D. Goebel W. S. (2010 ). Optimized cryopreservation method for human dental pulp-derived stem cells and their tissues of origin for banking and clinical use. Cryobiology 59 150–157.

    Not in our library10.1016/j.cryobiol.2009.06.005

  206. 206.

    Wu Y. Deng W. Babb M. Cancer R. Virginia W. Biology C. (2015a ). Exosomes: improved methods to characterize their morphology, RNA content, and surface protein biomarkers. Analyst 140 6631–6642.

    Not in our library10.1039/c5an00688k

  207. 207.

    Wu Y. Deng W. Klinke D. J. (2015b ). Exosomes: improved methods to characterize their morphology, RNA content, and surface protein biomarkers. Analyst 140 6631–6642.

    Not in our library10.1039/c5an00688k

  208. 208.

    Xin H. Li Y. Buller B. Katakowski M. Zhang Y. Wang X. (2012 ). Exosome-mediated transfer of miR-133b from multipotent mesenchymal stromal cells to neural cells contributes to neurite outgrowth. Stem Cells 30 1556–1564.

    Not in our library10.1002/stem.1129.exosome-mediated

  209. 209.

    Xin H. Li Y. Liu Z. Wang X. Shang X. Cui Y. (2013 ). MiR-133b promotes neural plasticity and functional recovery after treatment of stroke with multipotent mesenchymal stromal cells in rats via transfer of exosome-enriched extracellular particles. Stem Cells 31 2737–2746.

    Not in our library10.1002/stem.1409

  210. 210.

    Xu X. Liu Y. Cui Z. Wei Y. Zhang L. (2012 ). Effects of osmotic and cold shock on adherent human mesenchymal stem cells during cryopreservation. J. Biotechnol. 162 224–231.

    Not in our library10.1016/j.jbiotec.2012.09.004

  211. 211.

    Yang T. Martin P. Fogarty B. Brown A. Schurman K. Phipps R. (2015 ). Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in Danio rerio. Pharm. Res. 32 2003–2014.

    Not in our library10.1007/s11095-014-1593-y

  212. 212.

    Yu B. Kim H. W. Gong M. Wang J. Millard R. W. Wang Y. (2015 ). Exosomes secreted from GATA-4 overexpressing mesenchymal stem cells serve as a reservoir of anti-apoptotic microRNAs for cardioprotection. Int. J. Cardiol. 182 349–360.

    Not in our library10.1016/j.ijcard.2014.12.043

  213. 213.

    Zhang B. Wang M. Gong A. Zhang X. Wu X. Zhu Y. (2015a ). HucMSc-exosome mediated-Wnt4 signaling is required for cutaneous wound healing. Stem Cells 33 2158–2168.

    Not in our library10.1002/stem.1771

  214. 214.

    Zhang B. Wu X. Zhang X. Sun Y. Yan Y. Shi H. (2015b ). Human umbilical cord mesenchymal stem cell exosomes enhance angiogenesis through the Wnt4/beta-catenin pathway. Stem Cells Transl. Med. 4 513–522.

    Not in our library10.5966/sctm.2014-0267

  215. 215.
    Immunotherapeutic Potential of Extracellular Vesicles · 2014
    No notice
  216. 216.

    Zhang B. Yin Y. Lai R. C. Tan S. S. Choo A. B. H. Lim S. K. (2014b ). Mesenchymal stem cells secrete immunologically active exosomes. Stem Cells Dev. 23 1233–1244.

    Not in our library10.1089/scd.2013.0479

  217. 217.

    Zhang G. Zou X. Miao S. Chen J. Du T. Zhong L. (2014c ). The anti-oxidative role of micro-vesicles derived from human Wharton-Jelly mesenchymal stromal cells through NOX2/gp91(phox) suppression in alleviating renal ischemia-reperfusion injury in rats. PLoS One 9:e92129.

    Not in our library10.1371/journal.pone.0092129

  218. 218.
    Exosomes/tricalcium phosphate combination scaffolds can enhance bone regeneration by activating the PI3K/Akt signaling pathway · 2016
    No notice
  219. 219.

    Zhao B. Zhang Y. Han S. Zhang W. Zhou Q. Guan H. (2017 ). Exosomes derived from human amniotic epithelial cells accelerate wound healing and inhibit scar formation. J. Mol. Histol. 48 121–132.

    Not in our library10.1007/s10735-017-9711-x

  220. 220.

    Zhu Y. G. Feng X. M. Abbott J. Fang X. H. Hao Q. Monsel A. (2014 ). Human mesenchymal stem cell microvesicles for treatment of Escherichia coli endotoxin-induced acute lung injury in mice. Stem. Cells 32 116–125.

    Not in our library10.1002/stem.1504

  221. 221.

    Zimmermann E. Muller R. H. Mader K. (2000 ). Influence of different parameters on reconstitution of∖rlyophilized SLN. Int. J. Pharm. 196 211–213.

    Not in our library10.1016/s0378-5173(99)00424-x

Cited by papers we hold 10

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.